Physician profile
Keith E Jones
NPI 1811178031
$1,920.79
in general payments reported to CMS, 2019-2025
19 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $280 · 2023: $487 · 2024: $327 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $504.97 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $346.19 | 2021-2025 | |
| Mylan Specialty L.P. | $255.71 | 2021-2024 | Yupelri |
| Novo Nordisk INC | $154.72 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $145.79 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $80.87 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.05 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $57.89 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $48.02 | 2022 | |
| Supernus Pharmaceuticals, INC. | $47.14 | 2021-2025 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.85 | 2022-2023 | Xifaxan |
| Lilly USA, LLC | $34.39 | 2021-2024 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $33.62 | 2021 | |
| Viatris Specialty LLC | $24.77 | 2025 | Yupelri |
| Avanir Pharmaceuticals, INC. | $20.48 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $18.81 | 2024 | Dyanavel Xr |
| Exact Sciences Corporation | $15.29 | 2025 | The Cologuard Plus Collection Kit |
| Upsher-Smith Laboratories LLC | $12.52 | 2022 | |
| Merck Sharp & Dohme LLC | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.